Prescription Drug Pricing Policy: PBMs, formularies, and rebate terms defined

Definition and context: What prescription drug pricing policy covers

Prescription drug pricing policy refers to the rules and practices that determine how medicine prices are set, negotiated, and ultimately passed to patients at the pharmacy counter. The term covers list prices set by manufacturers, net prices after rebates and discounts, and patient out-of-pocket costs at point-of-sale, and it is central to debates about affordability and transparency.

Key actors include manufacturers who set list prices, pharmacies that dispense medications, insurers and plan sponsors who buy coverage for members, and pharmacy benefit managers who administer drug benefits and negotiate rebates on behalf of plans. Pharmacy benefit managers act as intermediaries that run formularies and manage utilization for many commercial plans and Medicare Part D sponsors, shaping which drugs patients pay less for at the counter, according to a recent explainer.

Policy settings for these actors come from multiple levels. Federal rules govern Medicare Part D formularies and beneficiary protections, while states vary in how they license and regulate PBMs, leading to inconsistent protections depending on where patients live, as documented in a federal review.

The practical concern of prescription drug pricing policy is how value and discounts move through contracts, and whether savings from manufacturer discounts lower what patients pay when they fill a prescription.

Role of PBMs in the drug supply chain

Pharmacy benefit managers provide services to plans that include formulary management, claims processing, and utilization management such as prior authorization and step therapy. These administrative functions determine which drugs are preferred on a plan and how access is managed.

PBMs also negotiate payments and financial terms with drug manufacturers and pharmacies. Those negotiations can include rebates from manufacturers in exchange for preferred placement on a formulary, and reimbursement terms with pharmacies that affect how pharmacies are paid for dispensed medicines, as a comprehensive explainer outlines.

PBMs carry out these activities under contracts with plan sponsors or insurers, and business models vary by contract and firm. That variation means the same PBM service can look different across employer plans, insurer products, and Medicare Part D sponsors.

How PBMs make money: rebates, fees, and spread pricing explained

One common PBM revenue stream is rebates, which are negotiated payments from manufacturers in return for favorable formulary placement or market access. Rebates can lower the net cost to the plan sponsor, but they often do not reduce the price a patient pays at the pharmacy counter.

PBMs may also collect administrative fees and use spread pricing, where the amount charged to a plan for a pharmacy claim exceeds the amount paid to the dispensing pharmacy. Combined with confidential contract terms, these payment flows can make it difficult for plan sponsors and consumers to see who retains value from manufacturer discounts, as investigative work has shown.

Formularies explained: tiers, utilization management, and patient access

A formulary is a plan’s list of covered drugs and the associated cost-sharing tiers that determine patient responsibility. Tiering commonly groups drugs into preferred and nonpreferred categories, with lower copays for preferred products and higher copays or coinsurance for others, which directly affects patients at point-of-sale.

Utilization management tools include prior authorization, which requires plan approval before a drug is covered, and step therapy, which asks patients to try lower-cost options first. These tools influence access and can shift which products become routine choices for prescribers and patients, consistent with federal Part D guidance.

Medicare Part D plans must follow federal standards for formularies and beneficiary protections, which shape how tiering and utilization management operate in the Part D market. Commercial plan formularies can vary more across states and insurers, creating different experiences for patients.

How rebate flows affect point-of-sale costs for patients

Research and policy analysis consistently find that negotiated rebates most commonly reduce net prices received by plan sponsors or insurers rather than directly lowering patient copays at the pharmacy. That separation of net and point-of-sale prices is a central reason policymakers consider rebate reforms.

Because rebates are often reconciled after a sale, patients paying a copay or coinsurance based on list price may not see any of the negotiated rebate at the time they buy a medicine. Analysts have proposed measures like rebate pass-through or point-of-sale rebate adjustments to address this gap, though evaluations show mixed short-term effects on out-of-pocket spending.

Evidence and systematic reviews note uncertainty about how quickly patients would benefit from rebate-focused reforms and call for careful evaluation of unintended consequences if reforms change incentives for coverage, pricing, or manufacturer behavior.

Medicare Part D rules and the formulary reference manual

The Medicare Part D formulary reference manual sets federal standards for plan formularies, including rules on tiering, exceptions, and beneficiary protections that plans must follow. These standards are a primary constraint on how Part D plans design coverage and use utilization management tools.

Part D protections specify how plans must handle exceptions requests, appeals, and notices that affect beneficiaries’ ability to access covered drugs. The manual provides practical rules that limit how plans set cost-sharing and when they must provide coverage alternatives for beneficiaries.

Compared with state-level variation in commercial markets, Part D represents a more uniform federal framework that directly affects millions of Medicare beneficiaries and shapes industry practices for formulary design.

State regulation of PBMs: variation and recent trends

A 2024 federal review found that state oversight of PBMs varies widely, producing uneven protections for consumers across the country. States have taken different approaches to licensing, disclosure, and limits on spread pricing, and enforcement differs by jurisdiction.

Common state policy actions include requiring PBM licensing, mandating transparency reporting, and restricting certain contracting practices such as spread pricing. However, differences in enforcement capacity and legal complexity can limit how these rules affect prices for patients.

Because state laws and implementations differ, researchers and policymakers note open questions about which approaches most reliably affect consumer costs. The GAO review and investigative reports highlight both policy options and limitations in evaluating effects across states.

Common contractual terms and why opacity matters

Many PBM contracts include confidential provisions that obscure how much is paid as rebates, fees, or retained as spread, which creates reporting gaps that make it difficult to trace payment flows. Investigative reporting has documented such opacity in contracts, stressing the challenge for payers and regulators.

When contract terms are confidential, plan sponsors and public overseers may lack the data needed to determine whether savings from manufacturer concessions are passed through to patients or retained within the insurer or plan. That uncertainty complicates efforts to measure who benefits from negotiated discounts.

Investigations and audits point to specific contract features that can hide payment flows, such as aggregate rebate reporting, carve-outs, and clauses that limit public disclosure. Those features drive calls for standardized reporting and greater transparency.

Policy options under discussion and their trade-offs

Policy discussions from recent years include rebate pass-through, which would require that rebates be returned to patients at point-of-sale, uniform rebate reporting so stakeholders can track flows, greater formulary transparency, and limits on spread pricing. Each option aims to reduce patient cost exposure or improve market clarity.

Analysts emphasize that reforms involve trade-offs. For example, moving rebates to point-of-sale may reduce list prices but could change negotiations between manufacturers and plans in ways that affect net prices, coverage choices, or innovation incentives, and evidence on immediate consumer benefit is mixed.

Reports recommend careful implementation, including phased pilots, standardized metrics, and legal review, because reforming contract mechanics can create complex downstream effects on plan design, pharmacy reimbursement, and manufacturer behavior.

How to evaluate PBM practices: criteria for payers, regulators, and consumers

Stakeholders can assess PBM contracts by looking for transparency in rebate flows, evidence that savings are passed to patients, and clear administrative fee structures. These criteria help determine whether contract terms align with goals like lowering out-of-pocket costs for patients.

Plan design features such as tiering, copays, and coinsurance interact with PBM practices. Evaluators should examine how formulary choices affect point-of-sale costs and whether utilization management rules create barriers that shift costs or access for patients.

Useful public records include state regulator filings, plan documents, and federal guidance on Part D rules, but evaluators should note that available data may still leave gaps that require targeted audits or disclosure requirements to fill.

Decision criteria for policymakers and plan sponsors

When weighing reforms, decision makers should consider expected effects on point-of-sale costs, feasibility of enforcement, legal risks, and how changes will affect market incentives. Evidence-based pilots and evaluation frameworks are recommended to test impacts before broad adoption.

Standardized reporting and metrics are critical to determine whether reforms meet goals. Without consistent data, policymakers cannot reliably measure whether patients are benefiting or whether reforms have unintended market consequences.

Policymakers should also consider phased approaches and pilot programs that allow for adjustment based on measured outcomes, and they should weigh enforcement capacity as a central factor in selecting reforms.

Typical errors and pitfalls for consumers and employers

Consumers often confuse list price with the out-of-pocket amount they will pay at the pharmacy. Copays and coinsurance can be based on different price measures, so checking plan details is important when choosing coverage.

Employers and plan sponsors should avoid relying solely on headline rebate totals without examining contract-level detail, because aggregate figures can mask whether rebates are retained by plans or returned to members. Asking for standardized reporting and audit rights can reduce that risk.

When evaluating plans, look for clear formulary descriptions, explanations of how cost-sharing is calculated, and any published transparency reports from PBMs or plan sponsors to better understand potential exposure to list price volatility.

Practical examples and scenarios: simplified case studies

Scenario A, employer plan with rebate pass-through: an employer negotiates a contract where manufacturer rebates tied to preferred placement must be returned to employees at point-of-sale. In this simplified case, employees who fill prescriptions see lower copays when rebates apply, but the plan sponsor also sees net budget changes that may require adjustments to premiums or formulary design, a dynamic noted in policy reviews.

Scenario B, Medicare Part D plan and tier changes: a Part D plan moves a costly drug to a higher cost-sharing tier and requires prior authorization. A beneficiary who needs the drug may face higher out-of-pocket costs unless an exceptions process approves coverage. Part D rules require specific beneficiary protections for these steps, which affects how beneficiaries can appeal and access treatments.

Where to find primary sources and next steps for readers

Key primary sources include the GAO review of state PBM regulation, the CMS Medicare Part D formulary reference manual, the KFF explainer on PBMs, Health Affairs policy summaries, investigative committee reports, and systematic reviews that evaluate rebate effects. Checking those documents can provide direct, sourced information on rules and evidence. Check those documents for updates related to this topic.

For local details, readers should consult state regulator pages and plan documents to see how PBM rules and plan designs apply in their state or for a specific employer plan. Open questions for 2026 include the effects of recent state laws and whether federal rulemaking will change contracting mechanics.

References and further reading

Additional relevant materials include state drug pricing transparency analyses and federal rulemaking that addresses disclosure and fee reporting. For implementation and legal context, stakeholders should review official notices and guidance.